Mesenchymal Stem Cells and Their Extracellular Vesicles Are a Promising Alternative to Antibiotics for Treating Sepsis
Sepsis is a life-threatening disease caused by the overwhelming response to pathogen infections. Currently, treatment options for sepsis are limited to broad-spectrum antibiotics and supportive care. However, the growing resistance of pathogens to common antibiotics complicates treatment efforts. Ex...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Bioengineering |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2306-5354/11/11/1160 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846154283844632576 |
|---|---|
| author | Yu Jiang Yunjuan Song Qin Zeng Bin Jiang |
| author_facet | Yu Jiang Yunjuan Song Qin Zeng Bin Jiang |
| author_sort | Yu Jiang |
| collection | DOAJ |
| description | Sepsis is a life-threatening disease caused by the overwhelming response to pathogen infections. Currently, treatment options for sepsis are limited to broad-spectrum antibiotics and supportive care. However, the growing resistance of pathogens to common antibiotics complicates treatment efforts. Excessive immune response (i.e., cytokine storm) can persist even after the infection is cleared. This overactive inflammatory response can severely damage multiple organ systems. Given these challenges, managing the excessive immune response is critical in controlling sepsis progression. Therefore, Mesenchymal stem cells (MSCs), with their immunomodulatory and antibacterial properties, have emerged as a promising option for adjunctive therapy in treating sepsis. Moreover, MSCs exhibit a favorable safety profile, as they are eventually eliminated by the host’s immune system within several months post-administration, resulting in minimal side effects and have not been linked to common antibiotic therapy drawbacks (i.e., antibiotic resistance). This review explores the potential of MSCs as a personalized therapy for sepsis treatment, clarifying their mechanisms of action and providing up-to-date technological advancements to enhance their protective efficacy for patients suffering from sepsis and its consequences. |
| format | Article |
| id | doaj-art-e65e65f5e976467daed8ca503de6a60d |
| institution | Kabale University |
| issn | 2306-5354 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Bioengineering |
| spelling | doaj-art-e65e65f5e976467daed8ca503de6a60d2024-11-26T17:52:08ZengMDPI AGBioengineering2306-53542024-11-011111116010.3390/bioengineering11111160Mesenchymal Stem Cells and Their Extracellular Vesicles Are a Promising Alternative to Antibiotics for Treating SepsisYu Jiang0Yunjuan Song1Qin Zeng2Bin Jiang3Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Chengdu 610041, ChinaR&D Division, Eureka Biotech Inc., Philadelphia, PA 19104, USANational Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610065, ChinaR&D Division, Eureka Biotech Inc., Philadelphia, PA 19104, USASepsis is a life-threatening disease caused by the overwhelming response to pathogen infections. Currently, treatment options for sepsis are limited to broad-spectrum antibiotics and supportive care. However, the growing resistance of pathogens to common antibiotics complicates treatment efforts. Excessive immune response (i.e., cytokine storm) can persist even after the infection is cleared. This overactive inflammatory response can severely damage multiple organ systems. Given these challenges, managing the excessive immune response is critical in controlling sepsis progression. Therefore, Mesenchymal stem cells (MSCs), with their immunomodulatory and antibacterial properties, have emerged as a promising option for adjunctive therapy in treating sepsis. Moreover, MSCs exhibit a favorable safety profile, as they are eventually eliminated by the host’s immune system within several months post-administration, resulting in minimal side effects and have not been linked to common antibiotic therapy drawbacks (i.e., antibiotic resistance). This review explores the potential of MSCs as a personalized therapy for sepsis treatment, clarifying their mechanisms of action and providing up-to-date technological advancements to enhance their protective efficacy for patients suffering from sepsis and its consequences.https://www.mdpi.com/2306-5354/11/11/1160sepsisantibiotics resistancemesenchymal stem cellsimmune-modulatorybioengineering |
| spellingShingle | Yu Jiang Yunjuan Song Qin Zeng Bin Jiang Mesenchymal Stem Cells and Their Extracellular Vesicles Are a Promising Alternative to Antibiotics for Treating Sepsis Bioengineering sepsis antibiotics resistance mesenchymal stem cells immune-modulatory bioengineering |
| title | Mesenchymal Stem Cells and Their Extracellular Vesicles Are a Promising Alternative to Antibiotics for Treating Sepsis |
| title_full | Mesenchymal Stem Cells and Their Extracellular Vesicles Are a Promising Alternative to Antibiotics for Treating Sepsis |
| title_fullStr | Mesenchymal Stem Cells and Their Extracellular Vesicles Are a Promising Alternative to Antibiotics for Treating Sepsis |
| title_full_unstemmed | Mesenchymal Stem Cells and Their Extracellular Vesicles Are a Promising Alternative to Antibiotics for Treating Sepsis |
| title_short | Mesenchymal Stem Cells and Their Extracellular Vesicles Are a Promising Alternative to Antibiotics for Treating Sepsis |
| title_sort | mesenchymal stem cells and their extracellular vesicles are a promising alternative to antibiotics for treating sepsis |
| topic | sepsis antibiotics resistance mesenchymal stem cells immune-modulatory bioengineering |
| url | https://www.mdpi.com/2306-5354/11/11/1160 |
| work_keys_str_mv | AT yujiang mesenchymalstemcellsandtheirextracellularvesiclesareapromisingalternativetoantibioticsfortreatingsepsis AT yunjuansong mesenchymalstemcellsandtheirextracellularvesiclesareapromisingalternativetoantibioticsfortreatingsepsis AT qinzeng mesenchymalstemcellsandtheirextracellularvesiclesareapromisingalternativetoantibioticsfortreatingsepsis AT binjiang mesenchymalstemcellsandtheirextracellularvesiclesareapromisingalternativetoantibioticsfortreatingsepsis |